Efficient Uptake of 177Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy

Bo Yu, Hao Wei, Qianjun He*, Carolina A. Ferreira, Christopher J. Kutyreff, Dalong Ni, Zachary T. Rosenkrans, Liang Cheng, Faquan Yu, Jonathan W. Engle, Xiaoli Lan, Weibo Cai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


The benefits to intracellular drug delivery from nanomedicine have been limited by biological barriers and to some extent by targeting capability. We investigated a size-controlled, dual tumor-mitochondria-targeted theranostic nanoplatform (Porphyrin-PEG Nanocomplexes, PPNs). The maximum tumor accumulation (15.6 %ID g−1, 72 h p.i.) and ideal tumor-to-muscle ratio (16.6, 72 h p.i.) was achieved using an optimized PPN particle size of approximately 10 nm, as measured by using PET imaging tracing. The stable coordination of PPNs with 177Lu enables the integration of fluorescence imaging (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and internal radiotherapy (RT). Furthermore, the efficient tumor and mitochondrial uptake of 177Lu-PPNs greatly enhanced the efficacies of RT and/or PDT. This work developed a facile approach for the fabrication of tumor-targeted multi-modal nanotheranostic agents, which enables precision and radionuclide-based combination tumor therapy.

Original languageEnglish (US)
Pages (from-to)218-222
Number of pages5
JournalAngewandte Chemie - International Edition
Issue number1
StatePublished - Jan 2 2018


  • combination therapy
  • multimodal imaging
  • nanotheranostics
  • radiotherapy
  • targeted delivery

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)


Dive into the research topics of 'Efficient Uptake of <sup>177</sup>Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy'. Together they form a unique fingerprint.

Cite this